IBDEI14N ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18825,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,18825,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,18826,0)
 ;;=D56.0^^94^916^21
 ;;^UTILITY(U,$J,358.3,18826,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18826,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,18826,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,18826,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,18827,0)
 ;;=D63.1^^94^916^23
 ;;^UTILITY(U,$J,358.3,18827,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18827,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,18827,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,18827,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,18828,0)
 ;;=D63.0^^94^916^24
 ;;^UTILITY(U,$J,358.3,18828,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18828,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,18828,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,18828,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,18829,0)
 ;;=D63.8^^94^916^22
 ;;^UTILITY(U,$J,358.3,18829,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18829,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,18829,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,18829,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,18830,0)
 ;;=C22.3^^94^916^25
 ;;^UTILITY(U,$J,358.3,18830,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18830,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,18830,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,18830,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,18831,0)
 ;;=D61.9^^94^916^26
 ;;^UTILITY(U,$J,358.3,18831,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18831,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,18831,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,18831,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,18832,0)
 ;;=D56.1^^94^916^28
 ;;^UTILITY(U,$J,358.3,18832,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18832,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,18832,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,18832,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,18833,0)
 ;;=C83.79^^94^916^29
 ;;^UTILITY(U,$J,358.3,18833,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18833,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,18833,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,18833,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,18834,0)
 ;;=C83.70^^94^916^30
 ;;^UTILITY(U,$J,358.3,18834,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18834,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,18834,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,18834,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,18835,0)
 ;;=D09.0^^94^916^37
 ;;^UTILITY(U,$J,358.3,18835,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18835,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,18835,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,18835,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,18836,0)
 ;;=D06.9^^94^916^38
 ;;^UTILITY(U,$J,358.3,18836,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18836,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,18836,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,18836,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,18837,0)
 ;;=D06.0^^94^916^40
 ;;^UTILITY(U,$J,358.3,18837,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18837,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,18837,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,18837,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,18838,0)
 ;;=D06.1^^94^916^41
 ;;^UTILITY(U,$J,358.3,18838,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18838,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,18838,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,18838,2)
 ;;=^5001939
